313 related articles for article (PubMed ID: 28395440)
41. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
Haferlach T; Schoch C; Löffler H; Gassmann W; Kern W; Schnittger S; Fonatsch C; Ludwig WD; Wuchter C; Schlegelberger B; Staib P; Reichle A; Kubica U; Eimermacher H; Balleisen L; Grüneisen A; Haase D; Aul C; Karow J; Lengfelder E; Wörmann B; Heinecke A; Sauerland MC; Büchner T; Hiddemann W
J Clin Oncol; 2003 Jan; 21(2):256-65. PubMed ID: 12525517
[TBL] [Abstract][Full Text] [Related]
42. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation.
Chen Y; Cortes J; Estrov Z; Faderl S; Qiao W; Abruzzo L; Garcia-Manero G; Pierce S; Huang X; Kebriaei P; Kadia T; De Lima M; Kantarjian H; Ravandi F
J Clin Oncol; 2011 Jun; 29(18):2507-13. PubMed ID: 21555694
[TBL] [Abstract][Full Text] [Related]
43. Conventional chemotherapy for acute myeloid leukemia: a Brazilian experience.
Pagnano KB; Traina F; Takahashi T; Oliveira GB; Rossini MS; Lorand-Metze I; Vigorito AC; Miranda EC; De Souza CA
Sao Paulo Med J; 2000 Nov; 118(6):173-8. PubMed ID: 11120548
[TBL] [Abstract][Full Text] [Related]
44. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
[TBL] [Abstract][Full Text] [Related]
45. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
46. Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols.
Sitges M; Boluda B; Garrido A; Morgades M; Granada I; Barragan E; Arnan M; Serrano J; Tormo M; Miguel Bergua J; Colorado M; Salamero O; Esteve J; Benavente C; Pérez-Encinas M; Coll R; Martí-Tutusaus JM; Brunet S; Sierra J; Ángel Sanz M; Montesinos P; Ribera JM; Vives S;
Eur J Haematol; 2020 Aug; 105(2):138-147. PubMed ID: 32243655
[TBL] [Abstract][Full Text] [Related]
47. Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation.
Jiang A; Jiang H; Brandwein J; Kamel-Reid S; Chang H
Leuk Res; 2011 Apr; 35(4):492-8. PubMed ID: 20684989
[TBL] [Abstract][Full Text] [Related]
48. FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation.
Yoshimoto G; Nagafuji K; Miyamoto T; Kinukawa N; Takase K; Eto T; Kato K; Hayashi S; Kamimura T; Ohno Y; Taniguchi S; Harada M
Bone Marrow Transplant; 2005 Dec; 36(11):977-83. PubMed ID: 16184177
[TBL] [Abstract][Full Text] [Related]
49. Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16).
Kainz B; Heintel D; Marculescu R; Schwarzinger I; Sperr W; Le T; Weltermann A; Fonatsch C; Haas OA; Mannhalter C; Lechner K; Jaeger U
Hematol J; 2002; 3(6):283-9. PubMed ID: 12522450
[TBL] [Abstract][Full Text] [Related]
50. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.
Brands-Nijenhuis AV; Labopin M; Schouten HC; Volin L; Socié G; Cornelissen JJ; Huynh A; Ljungman P; Malard F; Esteve J; Nagler A; Mohty M
Haematologica; 2016 Feb; 101(2):248-55. PubMed ID: 26589909
[TBL] [Abstract][Full Text] [Related]
51. [The clinical and prognostic significance of acute myeloid leukemia with FLT3-ITD].
Lin D; Wei H; Wang Y; Zhou CL; Liu BC; Liu KQ; Gong BF; Wei SN; Zhang GJ; Liu YT; Gong XY; Qiu SW; Mi YC; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2016 Dec; 37(12):1017-1021. PubMed ID: 28088961
[TBL] [Abstract][Full Text] [Related]
52. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.
Whitman SP; Archer KJ; Feng L; Baldus C; Becknell B; Carlson BD; Carroll AJ; Mrózek K; Vardiman JW; George SL; Kolitz JE; Larson RA; Bloomfield CD; Caligiuri MA
Cancer Res; 2001 Oct; 61(19):7233-9. PubMed ID: 11585760
[TBL] [Abstract][Full Text] [Related]
53. Prognostic significance of FLT3 internal tandem duplication in egyptian patients with acute myeloid leukemia with normal or favorable risk cytogenetics.
Shahin D; Aly R; Ebrahim MA
Egypt J Immunol; 2010; 17(2):23-32. PubMed ID: 23082484
[TBL] [Abstract][Full Text] [Related]
54. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Visani G; Bernasconi P; Boni M; Castoldi GL; Ciolli S; Clavio M; Cox MC; Cuneo A; Del Poeta G; Dini D; Falzetti D; Fanin R; Gobbi M; Isidori A; Leoni F; Liso V; Malagola M; Martinelli G; Mecucci C; Piccaluga PP; Petti MC; Rondelli R; Russo D; Sessarego M; Specchia G; Testoni N; Torelli G; Mandelli F; Tura S
Leukemia; 2001 Jun; 15(6):903-9. PubMed ID: 11417475
[TBL] [Abstract][Full Text] [Related]
55. [Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib].
Gu B; Chen GH; Shen HJ; Ma X; Fu CC; Han Y; Tang XW; Miao M; Qiu HY; Sun AN; Wu DP
Zhonghua Nei Ke Za Zhi; 2016 Apr; 55(4):293-7. PubMed ID: 27030618
[TBL] [Abstract][Full Text] [Related]
56. [Clinical study on combination of homoharringtonine, Ara-C and idarubicin induction for treatment of newly diagnosed acute myeloid leukemia patients].
Qin TJ; Xu ZF; Fang LW; Zhang HL; Zhang Y; Wang JZ; Pan LJ; Hu NB; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1277-82. PubMed ID: 22040988
[TBL] [Abstract][Full Text] [Related]
57. [Long-term survival results according to cytogenetic risk in patients with acute myeloid leukemia--singl center experience].
Piatkowska-Jakubas B; Mensah-Glanowska P; Salamańczuk Z; Skotnicki AB
Przegl Lek; 2011; 68(6):291-5. PubMed ID: 22039664
[TBL] [Abstract][Full Text] [Related]
58. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
[TBL] [Abstract][Full Text] [Related]
59. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.
Schoch C; Kern W; Schnittger S; Hiddemann W; Haferlach T
Leukemia; 2004 Jan; 18(1):120-5. PubMed ID: 14586477
[TBL] [Abstract][Full Text] [Related]
60. [FLT3-ITD Mutation in Newly Diagnosed Patients with Acute Promyelocytic Leukemia].
Gong BF; Wang Y; Lin D; Wei H; Li W; Zhou CL; Liu BC; Liu KQ; Zhang GJ; Liu YT; Li Y; Wei SN; Gong XY; Zhao XL; Qiu SW; Gu RX; Mi YC; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1615-1621. PubMed ID: 28024465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
